Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: Systematic review and meta-synthesis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Jackson, John W ^a,b   Schneeweiss, Sebastian ^a,b   VanderWeele, Tyler J ^b   Blacker, Deborah ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DROPERIDOL; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; ZIPRASIDONE;

ADVERSE OUTCOME; CAUSAL ATTRIBUTION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DELIRIUM; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFECT; DRUG SAFETY; HALLUCINATION; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; MORTALITY; PNEUMONIA; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DEMENTIA; HIP FRACTURES; META ANALYSIS;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DEMENTIA; HIP FRACTURES; HUMANS; PNEUMONIA;

EID: 84930431159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105376     Document Type: Review

References (75)

1. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (2011) Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 20: 177-184.
2. Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, et al (2007) American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 164: 5-56.
3. Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294: 1934-1943. (Pubitemid 41464695)
4. Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, et al (2012) Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol 32: 11-17.
5. Setoguchi S, Wang PS, Alan Brookhart M, Canning CF, Kaci L, et al (2008) Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 56: 1644-1650.
6. Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, et al (2012) Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 344: e977.
7. Smith Sehdev AE, Hutchins GM (2001) Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med 161: 277-284.
8. Roulson J, Benbow EW, Hasleton PS (2005) Discrepancies between clinical and autopsy diagnosis and the value of post mortem histology; a meta-analysis and review. Histopathology 47: 551-559. (Pubitemid 41775176)
9. Sesso HD, Gaziano JM, Glynn RJ, Buring JE (2006) Value of an Endpoints Committee versus the use of nosologists for validating cause of death. Contemp Clin Trials 27: 333-339. (Pubitemid 43928878)
10. Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, et al (2005) Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 17: 617-629. (Pubitemid 41758766)
11. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, et al (2005) Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 330: 445.
12. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, et al (2005) Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 165: 2677-2682. (Pubitemid 41785068)
13. Wang PS, Schneeweiss S, Setoguchi S, Patrick A, Avorn J, et al (2007) Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol 27: 707-710. (Pubitemid 351339462)
14. Sacchetti E, Trifiro G, Caputi A, Turrina C, Spina E, et al (2008) Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 22: 39-46.
15. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225-235.
16. Chan MC, Chong CS, Wu AY, Wong KC, Dunn EL, et al (2010) Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study. Int J Geriatr Psychiatry 25: 362-370.
17. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S (2011) Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 183: E411-419.
18. Huybrechts KF, Schneeweiss S, Gerhard T, Olfson M, Avorn J, et al (2012) Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 60: 420-429.
19. Trifiro G, Spina E, Gambassi G (2009) Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 59: 1-12.
20. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, et al (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169: 1952-1960.
21. Sacchetti E, Turrina C, Valsecchi P (2010) Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf 33: 273-288.
22. Brauer R, Douglas I, Smeeth L (2011) The association between antipsychotic agents and the risk of myocardial infarction: a systematic review. Br J Clin Pharmacol 72: 871-878.
23. Trifiro G (2011) Antipsychotic drug use and community-acquired pneumonia. Curr Infect Dis Rep 13: 262-268.
24. Zhang R, Dong L, Shao F, Tan X, Ying K (2011) Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry 44: 183-188.
25. Jonsson AK, Spigset O, Hagg S (2012) Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs 26: 649-662.
26. Oderda LH, Young JR, Asche CV, Pepper GA (2012) Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Ann Pharmacother 46: 917-928.
27. Pratt N, Roughead EE, Salter A, Ryan P (2012) Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol 12: 72.
28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62: e1-34.
29. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS (2007) Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 176: 627-632. (Pubitemid 46426056)
30. Gruneir A, Marras C, Fischer H, Wang X, Gill S, et al (2011) Confounders and intermediaries in case-control study designs: a strategy for distinguishing between the two when measured using the same variable. Pharmacoepidemiol Drug Saf 20: 221-228.
31. Murphy SL, Xu J, Kochanek KD (2012) Deaths: Preliminary Data for 2010. National Vital Statistics Report 60: 1-51.
32. Pearl J (2012) The causal mediation formula-a guide to the assessment of pathways and mechanisms. Prev Sci 13: 426-436.
33. Hafeman DM, Schwartz S (2009) Opening the Black Box: a motivation for the assessment of mediation. Int J Epidemiol 38: 838-845.
34. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353: 2335-2341. (Pubitemid 41713745)
35. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, et al (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146: 775-786. (Pubitemid 351650498)
36. Pratt N, Roughead EE, Ryan P, Salter A (2010) Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments. Pharmacoepidemiol Drug Saf 19: 699-707.
37. Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58: 323-337. (Pubitemid 40601980)
38. Liperoti R, Onder G, Landi F, Lapane KL, Mor V, et al (2009) All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 70: 1340-1347.
39. Rossom RC, Rector TS, Lederle FA, Dysken MW (2010) Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc 58: 1027-1034.
40. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, et al (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 169: 71-79.
41. Kales HC, Valenstein M, Kim HM, McCarthy JF, Ganoczy D, et al (2007) Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164: 1568-1576; quiz 1623.
42. Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, et al (2011) Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. Am J Epidemiol 174: 1089-1099.
43. Aparasu RR, Chatterjee S, Mehta S, Chen H (2012) Risk of death in dual-eligible nursing home residents using typical or atypical antipsychotic agents. Med Care 50: 961-969.
44. Schneeweiss S, Setoguchi S, Brookhart MA, Kaci L, Wang PS (2009) Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs 23: 171-180.
45. Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, et al (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 170: 1051-1058.
46. Swan JT, Fitousis K, Hall JB, Todd SR, Turner KL (2012) Antipsychotic use and diagnosis of delirium in the intensive care unit. Crit Care 16: R84.
47. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, et al (2004) Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 291: 1753-1762. (Pubitemid 38489897)
48. Wang S, Linkletter C, Dore D, Mor V, Buka S, et al (2012) Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. Stroke 43: 28-31.
49. Collins TC, Petersen NJ, Menke TJ, Souchek J, Foster W, et al (2003) Short-term, intermediate-term, and long-term mortality in patients hospitalized for stroke. J Clin Epidemiol 56: 81-87. (Pubitemid 36183319)
50. Soros P, Hachinski V (2012) Cardiovascular and neurological causes of sudden death after ischaemic stroke. Lancet Neurol 11: 179-188.
51. Haddad PM, Anderson IM (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62: 1649-1671. (Pubitemid 34848372)
52. Glassman AH, Bigger JT Jr (2001) Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 158: 1774-1782. (Pubitemid 33054769)
53. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, et al (1997) Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 30: 1500-1505. (Pubitemid 27486468)
54. Engdahl J, Holmberg M, Karlson BW, Luepker R, Herlitz J (2002) The epidemiology of out-of-hospital 'sudden' cardiac arrest. Resuscitation 52: 235-245. (Pubitemid 34211980)
55. Hagg S, Spigset O (2002) Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 16: 765-776.
56. Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, et al (2001) Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 76: 1102-1110. (Pubitemid 33032387)
57. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, et al (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5: 692-699. (Pubitemid 46563566)
58. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, et al (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159: 445-453. (Pubitemid 29108909)
59. Pierre JM (2005) Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 28: 191-208.
60. Salzman C, editor (2005) Clinical geriatric psychopharmacology. 4 ed. Philadelphia, PA: Lippincott Williams & Wilkins. 696 p.
61. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20: 1633-1650.
62. Maglione M, Ruelaz MA, Hu J, Wang Z, Shanman R, et al (2011) Off-label use of Atypical Antipsychotics: An Update. Rockville, MD: Agency for Healthcare Research and Quality.
63. Kikawada M, Iwamoto T, Takasaki M (2005) Aspiration and infection in the elderly: epidemiology, diagnosis and management. Drugs Aging 22: 115-130. (Pubitemid 40445322)
64. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20: 532-545. (Pubitemid 44528954)
65. Givens JL, Jones RN, Shaffer ML, Kiely DK, Mitchell SL (2010) Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 170: 1102-1107.
66. Kaplan V, Angus DC (2003) Community-acquired pneumonia in the elderly. Crit Care Clin 19: 729-748. (Pubitemid 37323355)
67. Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, et al (2003) Pneumonia: still the old man's friend? Arch Intern Med 163: 317-323. (Pubitemid 36183860)
68. Ogburn EL, VanderWeele TJ (2012) Analytic results on the bias due to nondifferential misclassification of a binary mediator. Am J Epidemiol 176: 555-561.
69. Ogburn EL, VanderWeele TJ (2012) On the nondifferential misclassification of a binary confounder. Epidemiology 23: 433-439.
70. Gareri P, De Fazio P, Manfredi VG, De Sarro G (2014) Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 34: 109-123.
71. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158: 915-920.
72. Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16: 241-249.
73. Maglione M, Center SCE-BP, RAND (2011) Off-label use of atypical antipsychotics: an update. Comparative effectiveness reviews. Rockville, MD: United States Agency for Healthcare Research and Quality.
74. Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, et al (2003) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull 29: 57-72. (Pubitemid 36871057)
75. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, et al (2009) The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8: 151-157.